NASDAQ:BRNS Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis → How Biden has already won 2024 (From Porter & Company) (Ad) Free BRNS Stock Alerts $2.27 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$2.21▼$2.4550-Day Range$2.05▼$3.6752-Week Range$1.64▼$5.10Volume4,606 shsAverage Volume19,824 shsMarket Capitalization$88.35 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Barinthus Biotherapeutics alerts: Email Address Barinthus Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside252.4% Upside$8.00 Price TargetShort InterestHealthy0.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.60) to ($2.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector704th out of 905 stocksPharmaceutical Preparations Industry328th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingBarinthus Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBarinthus Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Barinthus Biotherapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.04% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 39.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBarinthus Biotherapeutics does not currently pay a dividend.Dividend GrowthBarinthus Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRNS. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Barinthus Biotherapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for BRNS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Barinthus Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Barinthus Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.20% of the stock of Barinthus Biotherapeutics is held by institutions.Read more about Barinthus Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($2.60) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Barinthus Biotherapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Barinthus Biotherapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBarinthus Biotherapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Barinthus Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Barinthus Biotherapeutics Stock (NASDAQ:BRNS)Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Read More BRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRNS Stock News HeadlinesMay 7, 2024 | americanbankingnews.comBarinthus Biotherapeutics (NASDAQ:BRNS) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head-To-Head ReviewMay 4, 2024 | finance.yahoo.comIncreases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)May 9, 2024 | Weiss Ratings (Ad)Protect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …May 1, 2024 | globenewswire.comBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerApril 19, 2024 | markets.businessinsider.comInfection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed PerspectivesApril 18, 2024 | globenewswire.comBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsApril 14, 2024 | seekingalpha.comBRNS Barinthus Biotherapeutics plcMarch 22, 2024 | finance.yahoo.comBarinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023May 9, 2024 | Weiss Ratings (Ad)Protect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …March 20, 2024 | benzinga.comBarinthus Biotherapeutics: Q4 Earnings InsightsMarch 20, 2024 | globenewswire.comBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsMarch 4, 2024 | finance.yahoo.comIndividual investors account for 48% of Barinthus Biotherapeutics plc's (NASDAQ:BRNS) ownership, while institutions account for 25%February 25, 2024 | benzinga.comBarinthus Biotherapeutics Stock (NASDAQ:BRNS) Dividends: History, Yield and DatesSee More Headlines Receive BRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/09/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BRNS Previous SymbolNASDAQ:BRNS CUSIPN/A CIK1828185 Webwww.barinthusbio.com Phone44-1865-818-808FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+252.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,350,000.00 Net MarginsN/A Pretax Margin-9,541.40% Return on Equity-35.19% Return on Assets-30.80% Debt Debt-to-Equity RatioN/A Current Ratio12.45 Quick Ratio12.45 Sales & Book Value Annual Sales$800,000.00 Price / Sales110.44 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book0.47Miscellaneous Outstanding Shares38,920,000Free Float35,807,000Market Cap$88.35 million OptionableN/A Beta-0.45 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. William J. Enright MBA (Age 62)CEO & Director Comp: $969.44kDr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Comp: $593.48kMr. Graham Griffiths (Age 44)Chief Business Officer Comp: $522.23kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Secretary Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPGeoffrey LynnSenior Vice President of Synthetic ImmunotherapiesMore ExecutivesKey CompetitorsConnect BiopharmaNASDAQ:CNTBChimerixNASDAQ:CMRXCorvus PharmaceuticalsNASDAQ:CRVSSpero TherapeuticsNASDAQ:SPROBeyondSpringNASDAQ:BYSIView All Competitors BRNS Stock Analysis - Frequently Asked Questions Should I buy or sell Barinthus Biotherapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Barinthus Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BRNS shares. View BRNS analyst ratings or view top-rated stocks. What is Barinthus Biotherapeutics' stock price target for 2024? 2 brokerages have issued 12-month price targets for Barinthus Biotherapeutics' shares. Their BRNS share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 252.4% from the stock's current price. View analysts price targets for BRNS or view top-rated stocks among Wall Street analysts. How have BRNS shares performed in 2024? Barinthus Biotherapeutics' stock was trading at $3.69 at the beginning of the year. Since then, BRNS shares have decreased by 38.5% and is now trading at $2.27. View the best growth stocks for 2024 here. Are investors shorting Barinthus Biotherapeutics? Barinthus Biotherapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 14,100 shares, an increase of 39.6% from the March 31st total of 10,100 shares. Based on an average daily trading volume, of 22,000 shares, the short-interest ratio is currently 0.6 days. Currently, 0.0% of the shares of the stock are short sold. View Barinthus Biotherapeutics' Short Interest. When is Barinthus Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BRNS earnings forecast. How were Barinthus Biotherapeutics' earnings last quarter? Barinthus Biotherapeutics plc (NASDAQ:BRNS) announced its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.10. How do I buy shares of Barinthus Biotherapeutics? Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BRNS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
